Angela M DeMichele, MD MSCE

faculty photo
Alan and Jill Miller Professor in Breast Cancer Excellence
Co-Leader, Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania
Physician Leader, Breast Cancer Clinical Research Unit, Abramson Cancer Center, University of Pennsylvania
Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
Education:
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Description of Clinical Expertise

breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship

Selected Publications

Magbanua, M. J. M., van ‘t Veer, L., Clark, A. S., Chien, A. J., Boughey, J. C., Han, H. S., Wallace, A., Beckwith, H., Liu, M. C., Yau, C., Wileyto, E. P., Ordonez, A., Solanki, T. I., Hsiao, F., Lee, J. C., Basu, A., Brown Swigart, L., Perlmutter, J., Delson, A. L., Bayne, L., DeLuca, S., Yee, S. S., Carpenter, E. L., Esserman, L. J., Park, J. W., Chodosh, L. A., DeMichele, A. : Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Research and Treatment 198, Jan 2023.

Clark AS, Cobain EF, Dayao Z, Somerfield MR, DeMichele A, & Henry NL: Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A. JCO Oncol Pract Sep 2022 Notes: Online ahead of print.

Thakran S, Cohen E, Jahani N, Weinstein S.P, Pantalone L, Hylton N, Newit D, DeMichele A, Davatzikos C, Kontos D.: Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial. Transl Oncol. Page: 20:101411, Jun 2022.

Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan, KM Sharma, P Shatsky, R Stringer-Reasor, E Telli, M Turner, N.C & DeMichele A. : Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology Jun 2022 Notes: online ahead of print.

Makhlin I, DeMichele A.: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med. 3(6): 100668, June 2022.

Makhlin I, & DeMichele A: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med. 3(6), Jun 2022.

Cristofanilli M, Rugo H.S, Im S.A, Slamon D.J, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean M.J, Turner N.C. : Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study. Clin Cancer Res. May 2022 Notes: online ahead of print.

Brown J.C, Sturgeon K, Sarwer D.B, Troxel A.B, DeMichele A.M, Denlinger C.S, Schmitz K.H.: The effects of exercise and diet on sex steroids in breast cancer survivors. Endocr Relat Cancer. May 2022 Notes: online ahead of print.

Martei Y.M, Narasimhamurthy M, Setlhako D.I, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman L.N, Grover S, DeMichele A.: Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy. JCO Glob Oncol. Page: e2200016. May 2022.

Pfeiler G, DeMichele A, Dueck AC, Fesl C, Gnant M, & Mayer EL. : Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic. Lancet Oncol. 23(2): 195-197, Feb 2022.

back to top
Last updated: 09/15/2023
The Trustees of the University of Pennsylvania